Company News Summary
Starpharma Reports Negative Cash Flow of $7.34m for the September 2021 Quarter
19 Jan 2022 | 21:16:00 | Associate analysts | Increase | Decrease | 
Original announcement: Quarterly Cashflow and Activities Report
Starpharma reported negative cash flow of $7.34m for quarter ended 30 September 2021. Operating cash flow for the period was $(7.01m). Investing cash flow was $(153,000). Financing cash flow was $(176,000). Cash in hand at the end of the quarter was $53.37m. During the quarter, following signing of the recent supply arrangement, VIRALEZE antiviral nasal spray is expected to be launched in Vietnam in November, with the first delivery into Vietnam expected in early November. Vietnam, which has a population of 97m, is experiencing a Delta outbreak with 23 per cent of its population fully vaccinated.
Consolidated Statement of Cash Flow for the Quarter ended 30 September 2021
| Current Quarter $A'000- 30 September 2021 | Year to Date $A'000-3 Months | |
| Net Operating Cash Flows | (7,013) | (7,013) |
| Net Investing Cash Flows | (153) | (153) |
| Total Operating and Investing Cash Flows | (7,166) | (7,166) |
| Net Financing Cash Flows | (176) | (176) |
| Net Increase (Decrease) in Cash Held | (7,342) | (7,342) |
| Cash at Beginning of Quarter/Year to Date | 60,500 | 60,500 |
| Cash at End of Quarter | 53,373 | 53,373 |
See more ASX300 News Announcements